Portal de investigação
Comparative effectiveness of Anti-IL5 and Anti-IgE biologic classes in patients with severe asthma eligible for both
Data de publicação:
Data Ahead of Print:
Autores da FMUP
Participantes de fora da FMUP
- Pfeffer, PE
- Ali, N
- Murray, R
- Ulrik, C
- Tran, TN
- Maspero, J
- Peters, M
- Christoff, GC
- Sadatsafavi, M
- Torres-Duque, CA
- Altraja, A
- Lehtimäki, L
- Papadopoulos, NG
- Salvi, S
- Costello, RW
- Cushen, B
- Heffler, E
- Iwanaga, T
- Al-Ahmad, M
- Larenas-Linnemann, D
- Kuna, P
- Al-Lehebi, R
- Rhee, CK
- Perez-de-Llano, L
- Steve, DWP
- Mahboub, B
- Wang, E
- Goh, C
- Lyu, J
- Newell, A
- Alacqua, M
- Belevskiy, AS
- Bhutani, M
- Bjermer, L
- Bjornsdottir, U
- Bourdin, A
- von Boulow, A
- Busby, J
- Canonica, GW
- Cosio, BG
- Dorscheid, DR
- Muñoz-Esquerre, M
- FitzGerald, JM
- Gil, EG
- Gibson, PG
- Heaney, LG
- Hew, M
- Hilberg, O
- Hoyte, F
- Jackson, DJ
- Koh, MS
- Ko, HKB
- Lee, JH
- Lehmann, S
- Loureiro, CC
- Lúdvíksdóttir, D
- Menzies-Gow, AN
- Mitchell, P
- Papaioannou, AI
- Popov, TA
- Porsbjerg, CM
- Salameh, L
- Sirena, C
- Taillé, C
- Taube, C
- Tohda, Y
- Wechsler, ME
- Price, DB
Unidades de investigação
Abstract
BackgroundPatients with severe asthma may present with characteristics representing overlapping phenotypes, making them eligible for more than one class of biologic. Our aim was to describe the profile of adult patients with severe asthma eligible for both anti-IgE and anti-IL5/5R and to compare the effectiveness of both classes of treatment in real life. MethodsThis was a prospective cohort study that included adult patients with severe asthma from 22 countries enrolled into the International Severe Asthma registry (ISAR) who were eligible for both anti-IgE and anti-IL5/5R. The effectiveness of anti-IgE and anti-IL5/5R was compared in a 1:1 matched cohort. Exacerbation rate was the primary effectiveness endpoint. Secondary endpoints included long-term-oral corticosteroid (LTOCS) use, asthma-related emergency room (ER) attendance, and hospital admissions. ResultsIn the matched analysis (n = 350/group), the mean annualized exacerbation rate decreased by 47.1% in the anti-IL5/5R group and 38.7% in the anti-IgE group. Patients treated with anti-IL5/5R were less likely to experience a future exacerbation (adjusted IRR 0.76; 95% CI 0.64, 0.89; p < 0.001) and experienced a greater reduction in mean LTOCS dose than those treated with anti-IgE (37.44% vs. 20.55% reduction; p = 0.023). There was some evidence to suggest that patients treated with anti-IL5/5R experienced fewer asthma-related hospitalizations (IRR 0.64; 95% CI 0.38, 1.08), but not ER visits (IRR 0.94, 95% CI 0.61, 1.43). ConclusionsIn real life, both anti-IgE and anti-IL5/5R improve asthma outcomes in patients eligible for both biologic classes; however, anti-IL5/5R was superior in terms of reducing asthma exacerbations and LTOCS use.
© 2023 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Dados da publicação
- ISSN/ISSNe:
- 0105-4538, 1398-9995
- Tipo:
- Article
- Páginas:
- 1934-1948
- DOI:
- 10.1111/all.15711
- Link para outro recurso:
- www.scopus.com
ALLERGY Wiley-Blackwell Publishing Ltd
Citações Recebidas na Web of Science: 3
Citações Recebidas na Scopus: 11
Documentos
- Não há documentos
Filiações
Keywords
- biologics; exacerbation; ISAR; oral corticosteroids; real life
Campos de estudo
Financiamento
Proyectos asociados
Prevalence and Characterisation of Asthma Patients According to Disease Severity in Portugal (EPI-ASTHMA) - NCT05169619
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Observacional (EPI-ASTHMA) . AstraZeneca . 2021
Effect of a Mobile App on Improving Asthma Control in Adolescents and Adults With Persistent Asthma: A Pilot Randomized Multicentre, Superiority Clinical Trial (mINSPIRERS) - NCT05129527
Investigador Principal: João de Almeida Lopes da Fonseca
Ensaio Clínico Académico (mINSPIRERS) . 2021
Utilização em estudos observacionais do Registo de Asma Grave Portugal.
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Observacional Académico (RAG) . 2020
Clinical Research Collaboration Severe Heterogenous Asthma Research collaboration, Patient-centered (CRC SHARP).
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Observacional (SHARP) . European Respiratory Society . 2021
Multidimensional phenotyping of severe asthma patients and its impact on disease control and therapeutic response - analysis from the Portuguese Severe Asthma Registry.
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Observacional (RAG-SPP-GSK) . SPPneumologia . 2022
BREATHE - An oBservational, pRimary data study to characterize severe AsThma pHenotypes and assEss disease burden across the EUCAN region.
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Observacional (RAG-AZ-BREATHE) . AstraZeneca . 2022
Efficiency in Spine Care ? Assessing outcomes and costs to inform healthcare improvement
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Académico . 2022
Use of secondary data, health technology assessment methods and economic modelling applied to penicillin allergy
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Académico . 2020
Using different data sources for the identification of asthma patients and those at high risk of adverse outcomes
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Académico . 2020
Phenotypes of Chronic Diseases of the Airways: Towards Multidimensional Data -Driven Profiling
Investigador Principal: João de Almeida Lopes da Fonseca
Estudo Clínico Académico . 2020
Citar a publicação
Pfeffer PE,Ali N,Murray R,Ulrik C,Tran TN,Maspero J,Peters M,Christoff GC,Sadatsafavi M,Torres CA,Altraja A,Lehtimäki L,Papadopoulos NG,Salvi S,Costello RW,Cushen B,Heffler E,Iwanaga T,Al M,Larenas D,Kuna P,Fonseca JA,Al R,Rhee CK,Perez L,Steve DWP,Mahboub B,Wang E,Goh C,Lyu J,Newell A,Alacqua M,Belevskiy AS,Bhutani M,Bjermer L,Bjornsdottir U,Bourdin A,von A,Busby J,Canonica GW,Cosio BG,Dorscheid DR,Muñoz M,FitzGerald JM,Gil EG,Gibson PG,Heaney LG,Hew M,Hilberg O,Hoyte F,Jackson DJ,Koh MS,Ko HKB,Lee JH,Lehmann S,Loureiro CC,Lúdvíksdóttir D,Menzies AN,Mitchell P,Papaioannou AI,Popov TA,Porsbjerg CM,Salameh L,Sirena C,Taillé C,Taube C,Tohda Y,Wechsler ME,Price DB. Comparative effectiveness of Anti-IL5 and Anti-IgE biologic classes in patients with severe asthma eligible for both. Allergy. 2023. 78. (7):p. 1934-1948. IF:12,400. (1).
